Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$967.6M
89M shares
52-week range
$5.45 – $12.49
78% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $53.9M | $67.5M |
| Cost of revenue | $10.0K | $0 | $194.0K | $0 | $0 | $849.0K | $0 | $57.0K |
| Gross profit | −$10.0K | $0 | −$194.0K | $0 | $0 | −$849.0K | $53.9M | $67.4M |
| Gross margin | — | — | — | — | — | — | 100.0% | 99.9% |
| R&D | $46.8M | $47.8M | $60.4M | $84.7M | $92.8M | $115.2M | $170.0M | $251.1M |
| Operating income | −$62.9M | −$67.5M | −$91.9M | −$131.3M | −$139.9M | −$165.8M | −$193.2M | −$303.6M |
| EBITDA | −$62.9M | −$67.5M | −$88.9M | −$129.5M | −$134.9M | −$150.2M | −$169.5M | −$275.8M |
| Net income | −$60.4M | −$63.1M | −$89.6M | −$130.5M | −$135.8M | −$152.6M | −$174.0M | −$278.7M |
| Net margin | — | — | — | — | — | — | -322.9% | -412.9% |
| EPS (diluted) | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $95M | $-3.54 | $-3.85–$-2.86 | 9 |
| 2027 | $215M | $-2.65 | $-3.28–$-1.97 | 9 |
| 2028 | $298M | $-2.00 | $-3.19–$-0.35 | 10 |
| 2029 | $522M | $-0.24 | $-0.49–$-0.13 | 4 |
Forward consensus · source: Financial Modeling Prep
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
www.kuraoncology.comNo one on the platform currently holds KURA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,582,568 | $12.9M |
No one on the platform has traded KURA yet.
| -0.81% |
| $666M |
| — |
| PROKProKidney Corp. | $2.04 | +7.94% | $686M | — |
| REPLReplimune Group, Inc. | $11.07 | -1.16% | $914M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$KURA Been quietly adding here over the last couple of months...
View on StockTwits ↗$SLS $KURA dude the AML space is not that large thank God. For SLS to be worth $100+ makes no sense. Selling my shares and investing elsewhere soon 😉
View on StockTwits ↗$KURA I really believe we will see $20 and above this year
View on StockTwits ↗$KURA Lets go!!! 100% confident we havea blockbuster!
View on StockTwits ↗$KURA Anyone that looks at this stock will buy it. Just a matter of eyeballs. $1.1B in successful R&D for free.
View on StockTwits ↗@revuelto Kura Oncology ($KURA) is primed for a premium buyout between **mid-to-late 2027**, a timeline forced by clinical data maturation and the historical 24-month commercial decay penalty. By then, KOMZIFTI (ziftomenib) will have solidified its frontline (1L) AML market path via the flawless 96% CRc data and the enrolling Phase 3 KOMET-017 master protocol, locking in a multi-billion-dollar valuation floor. Simultaneously, Kura will deliver mature progression-free survival (PFS) data for darlifarnib, proving it is the universal "companion rescue" asset required to protect Big Pharma's massive KRAS solid tumor market. Confronted with a de-risked 1L leukemia blockbuster and an essential KRAS resistance platform, suitors will trigger a fierce bidding war. CEO Troy Wilson will leverage this dual-engine catalyst to exit the equity at a $70+ premium before the November 2027 commercialization deadline.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.